Inclusion Criteria:~* Diagnosis of Alzheimer's Disease (AD), encompassing probable AD and mild cognitive
impairment due to AD (MCI-AD) based on the 2011 National Institute on Aging and Alzheimer's Association
(NIA/AA) criteria~* Documented PET scan that is positive for amyloid~* Mini-Mental State Examination (MMSE)
score of 16-27 (inclusive), subject to stratification requirements~* Global Clinical Dementia Rating (CDR) of
0.5 to 2 (if 0.5, including a score of >0 in one of the functional domains: Community Affairs, Home and
Hobbies, or Personal Care)~* Age <90 years~* Females must be surgically sterile, have undergone bilateral tubal
occlusion / ligation, be post-menopausal, or use adequate contraception~* Subject, and/or, in the case of
reduced decision-making capacity, legally acceptable representative(s) consistent with local and national law
is/are able to read, understand, and provide written informed consent in the designated language of the study
site~* Has one or more identified adult study partner who either lives with the subject or has sufficient
contact to provide assessment of changes in subject behavior and function over time and information on safety
and tolerability; is willing to provide written informed consent for his/her own participation; is able to
read, understand, and speak the designated language(s) at the study site; agrees to accompany the subject to
each study visit; and is able to verify daily compliance with study drug~* Must not be taking an
acetylcholinesterase inhibitor and/or memantine for at least 60 days at the time of the Baseline assessments~*
Able to comply with the study procedures in the view of the Investigator~
